DnB Asset Management
CPRX

DnB Asset Management’s Catalyst Pharmaceutical CPRX Stock Holding History

DnB Asset Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$212K Buy
+6,761
New +$200K ﹤0.01% 1187

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

DnB Asset Management's CPRX Position: Q2 2026 in Review

DnB Asset Management opened a new position in Catalyst Pharmaceutical (CPRX) in Q2 2026: 6,761 shares worth $212K. The stake represents ﹤0.01% of the portfolio and ranks #1187 among its holdings.

396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • DnB Asset Management held 6,761 shares of Catalyst Pharmaceutical worth $212K as of Q2 2026.
  • Catalyst Pharmaceutical was a new DnB Asset Management position in Q2 2026.
  • Catalyst Pharmaceutical made up ﹤0.01% of DnB Asset Management's portfolio in Q2 2026, its #1187 holding.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on DnB Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.